PCSK9 INHIBITION AND AORTIC STENOSIS IN THE FOURIER TRIAL

被引：0
|
作者：
Bergmark, Brian [1 ]
O'Donoghue, Michelle [1 ]
Murphy, Sabina [1 ]
Kuder, Julia [1 ]
Ezhov, Marat V. [1 ]
Ceska, Richard [1 ]
Gouni-Berthold, Ioanna [1 ]
Jensen, Henrik Kjaerulf [1 ]
Tokgozoglu, Sadberk Lale [1 ]
Mach, Francois [1 ]
Huber, Kurt [1 ]
Gaciong, Zbigniew [1 ]
Lewis, Basil S. [1 ]
Schiele, Francois [1 ]
Jukema, Johan Wouter [1 ]
Pedersen, Terje [1 ]
Giugliano, Robert [1 ]
Sabatine, Marc Steven [1 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2020年 / 75卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
914-08
引用
收藏
页码：2112 / 2112
页数：1
相关论文
共 50 条
  • [1] Genetic and In Vitro Inhibition of PCSK9 and Calcific Aortic Valve Stenosis
    Perrot, Nicolas
    Valerio, Vincenza
    Moschetta, Donato
    Boekholdt, S. Matthijs
    Dina, Christian
    Chen, Hao Yu
    Abner, Erik
    Martinsson, Andreas
    Manikpurage, Hasanga D.
    Rigade, Sidwell
    Capoulade, Romain
    Mass, Elvira
    Clavel, Marie-Annick
    Le Tourneau, Thierry
    Messika-Zeitoun, David
    Wareham, Nicholas J.
    Engert, James C.
    Polvani, Gianluca
    Pibarot, Philippe
    Esko, Tonu
    Smith, J. Gustav
    Mathieu, Patrick
    Thanassoulis, George
    Schott, Jean-Jacques
    Bosse, Yohan
    Camera, Marina
    Theriault, Sebastien
    Poggio, Paolo
    Arsenault, Benoit J.
    JACC-BASIC TO TRANSLATIONAL SCIENCE, 2020, 5 (07): : 649 - 661
  • [2] Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial
    O'Donoghue, Michelle L.
    Fazio, Sergio
    Giugliano, Robert P.
    Stroes, Erik S. G.
    Kanevsky, Estella
    Gouni-Berthold, Ioanna
    Im, KyungAh
    Pineda, Armando Lira
    Wasserman, Scott M.
    Ceska, Richard
    Ezhov, Marat V.
    Jukema, J. Wouter
    Jensen, Henrik K.
    Tokgozoglu, S. Lale
    Mach, Francois
    Huber, Kurt
    Sever, Peter S.
    Keech, Anthony C.
    Pedersen, Terje R.
    Sabatine, Marc S.
    CIRCULATION, 2019, 139 (12) : 1483 - 1492
  • [3] LIPOPROTEIN(A), PCSK9 INHIBITION AND CARDIOVASCULAR RISK: INSIGHTS FROM THE FOURIER TRIAL
    O'Donoghue, M.
    Giugliano, R.
    Keech, A.
    Kanevsky, E.
    Im, K.
    Lira, A.
    Pineda, A. Lira
    Somaratne, R.
    Sever, P.
    Pederson, T.
    Sabatine, M.
    ATHEROSCLEROSIS, 2018, 275 : E9 - E10
  • [4] Effects of PCSK9 Inhibition on Plasma PCSK9 Concentration and Hepatic PCSK9 Expression
    Shapiro, Michael D.
    Tavori, Hagai
    Oleaga, Carlota
    Miles, Joshua
    Fazio, Sergio
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2018, 38
  • [5] PCSK9 and Calcific Aortic Valve Stenosis Moving Beyond Lipids
    Leopold, Jane A.
    JACC-BASIC TO TRANSLATIONAL SCIENCE, 2020, 5 (07): : 662 - 664
  • [6] PCSK9 inhibition in PAD
    Huynh, Karina
    NATURE REVIEWS CARDIOLOGY, 2018, 15 (01) : 4 - 5
  • [7] PCSK9 inhibition in PAD
    Karina Huynh
    Nature Reviews Cardiology, 2018, 15 : 4 - 5
  • [8] The promises of PCSK9 inhibition
    Petrides, Francine
    Shearston, Kate
    Chatelais, Mathias
    Guilbaud, Florian
    Meilhac, Olivier
    Lambert, Gilles
    CURRENT OPINION IN LIPIDOLOGY, 2013, 24 (04) : 307 - 312
  • [9] Update on PCSK9 inhibition
    Katzmann, Julius L.
    Custodis, Florian
    Schirmer, Stephan H.
    Laufs, Ulrich
    HERZ, 2022, 47 (03) : 196 - 203
  • [10] PCSK9 inhibition in the Fourier study: even lower – even better!
    Möhlenkamp S.
    Der Kardiologe, 2017, 11 (5): : 361 - 362
12345